查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609617

勃起功能障礙藥物市場規模、佔有率、趨勢分析報告：依產品、劑型、地區、細分市場預測，2025-2030 年

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

勃起功能障礙藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2025年至2030年全球勃起功能障礙藥物市場將以9.13%的複合年成長率成長，2030年達到49億美元。

勃起功能障礙的日益流行預計將有助於市場的成長。根據歐洲泌尿系統的數據，2020 年歐洲 40-70 歲男性族群中 ED 的總體盛行率約為 52%。根據波士頓大學醫學院的數據，大約 22.0% 的 40 多歲男性和 49.0% 的 70 多歲男性患有勃起功能障礙。因此，預計在預測期內，老年人口的增加將增加 ED 的盛行率，並有望為市場創造有利的成長機會。

禮來公司透過禮來公司病患支援計畫 (LPSP) 提供低成本藥物來幫助 ED 患者。該計劃為加拿大合格的未投保 ED 患者提供經濟援助，並且該計劃可能需要註冊。因此，犀利士品牌版中此類援助計畫的存在可能會使低收入患者更負擔得起，也可能導致收益增加。此外，公司正在採取聯盟和夥伴關係等舉措，在國外市場製造和商業化其產品。例如，2022 年 1 月，Petros Pharmaceuticals, Inc. 與全球受託製造廠商(CDMO) 合作，進行阿伐那非錠劑的商業生產。此次合作旨在取代與 Vivas 的現有合約並提供持續的產品供應。

此外，根據國家醫學圖書館（2021）的數據，四川海絲古藥業有限公司在中國當地開展了一項評估 Stendra 對 ED 患者安全性和有效性的 3 期臨床試驗。臨床試驗結果顯示，兩種劑量的 Stendra 100mg 和 200mg 對中國 ED 患者的治療效果有所改善。這項臨床療效的證明可能會加強 Strenda (Avanafil) 的市場地位。然而，對勃起功能障礙缺乏認知、對治療感到羞恥、假陽性理論、圍繞疾病的社會恥辱、缺乏謹慎等可能會抑制市場成長。根據歐洲泌尿系統協會（EAU）的一項調查，只有18%的西班牙人聽說過ED治療，而68.0%的人相信其有效性。

勃起功能障礙藥物市場報告亮點

  • 按產品分類，由於威而鋼在全球範圍內的供應以及 ED 患者對該產品的認知度不斷提高，威而鋼細分市場將在 2024 年佔據最大的市場佔有率。
  • 北美主導勃起功能障礙藥物市場，2024年佔50.54%的銷售佔有率。這是由於該地區的高疾病負擔、強大的醫療基礎設施以及新治療產品的快速核准。
  • 2024年，口服市場佔有率，為84.03%。口服給藥因其方便、非侵入性和廣泛的患者偏好而成為市場的主導部分。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章勃起功能障礙藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 勃起功能障礙藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章勃起功能障礙藥物市場：產品評估與趨勢分析

  • 細分儀表板
  • 勃起功能障礙藥物市場：產品波動分析
  • 勃起功能障礙藥物市場：按產品分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 威而鋼（檸檬酸Sildenafil）
  • 犀利士（他達拉非）
  • Stendra/Spedra（阿伐那非）
  • Jydena（Udenafil）
  • 其他藥品

第5章勃起功能障礙藥物市場：給藥方法的估計與趨勢分析

  • 細分儀表板
  • 勃起功能障礙藥物市場：給藥方法變化分析
  • 勃起功能障礙藥物市場：按給藥方法分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 口服給藥方法
  • 給藥方法 注射
  • 其他給藥方法

第6章 勃起功能障礙藥物市場：區域估計與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 主要企業簡介
    • Bayer AG
    • Lilly
    • GlaxoSmithKline PLC
    • Petros Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd
    • Lupin Limited
    • Futura Medical
    • Cure Pharmaceutical
    • 23andMe
    • Hims &Hers Health, Inc.
    • RO
    • BlueChew
    • GoodRx, Inc.
Product Code: 978-1-68038-604-2

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.90 billion by 2030, expanding at a CAGR of 9.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

  • By product, the viagra segment held the largest market share in 2024 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
  • North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 50.54% in 2024, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
  • The oral mode segment accounted for the largest market share of 84.03% in 2024. The oral mode of administration is a dominant segment in the market, driven by its convenience, non-invasive nature, and widespread patient preference

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mode of Administration
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of erectile dysfunction
      • 3.2.1.2. Rising geriatric population
      • 3.2.1.3. Increasing research & development (R&D)
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of healthcare infrastructure and manufacturing errors
      • 3.2.2.2. Lack of awareness about erectile dysfunction
  • 3.3. Erectile Dysfunction Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Erectile Dysfunction Drugs Market: Product Movement Analysis
  • 4.3. Erectile Dysfunction Drugs Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Viagra (sildenafil citrate)
    • 4.5.1. Viagra (sildenafil citrate) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cialis (Tadalafil)
    • 4.6.1. Cialis (Tadalafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Stendra/Spedra (avanafil)
    • 4.7.1. Stendra/Spedra (avanafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Zydena (udenafil)
    • 4.8.1. Zydena (udenafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Other Drugs
    • 4.9.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Mode of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Erectile Dysfunction Drugs Market: Mode of Administration Movement Analysis
  • 5.3. Erectile Dysfunction Drugs Market by Mode of Administration Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Oral Mode of Administration
    • 5.5.1. Oral Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Injectable Mode of Administration
    • 5.6.1. Injectable Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Modes of Administration
    • 5.7.1. Other Modes of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Bayer AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Lilly
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. GlaxoSmithKline PLC
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Petros Pharmaceuticals, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Pfizer Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Teva Pharmaceutical Industries Ltd
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Lupin Limited
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Futura Medical
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Cure Pharmaceutical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. 23andMe
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Hims & Hers Health, Inc.
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. RO
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Product benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. BlueChew
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Product benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. GoodRx, Inc.
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Product benchmarking
      • 7.4.14.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 4. Global Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 5. North America Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 6. North America Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 7. U.S. Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 8. U.S. Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 9. Canada Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 10. Canada Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 11. Mexico Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 12. Mexico Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 13. Europe Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 14. Europe Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 15. UK Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 16. UK Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 17. Germany Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 18. Germany Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 19. France Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 20. France Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 21. Italy Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 22. Italy Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 23. Spain Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 24. Spain Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 25. Denmark Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 26. Denmark Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 27. Sweden Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 28. Sweden Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 29. Norway Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 30. Norway Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 31. Asia Pacific Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 32. Asia Pacific Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 33. Japan Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 34. Japan Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 35. China Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 36. China Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 37. India Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 38. India Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 39. Australia Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 40. Australia Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 41. South Korea Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 42. South Korea Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 43. Thailand Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 44. Thailand Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 45. Latin America Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 46. Latin America Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 47. Brazil Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 48. Brazil Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 49. Argentina Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 50. Argentina Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 51. Middle East & Africa Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 52. Middle East & Africa Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 53. South Africa Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 54. South Africa Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 55. Saudi Arabia Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 56. Saudi Arabia Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 57. UAE Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 58. UAE Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 59. Kuwait Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 60. Kuwait Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Erectile Dysfunction Drugs market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Erectile Dysfunction Drugs market, Product outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 12 Viagra (sildenafil citrate) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Cialis (tadalafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Levitra/Staxyn (vardenafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Stendra/Spedra (avanafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Zydena (udenafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Other drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Erectile Dysfunction Drugs market, Mode of Administration outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 19 Oral mode of administration market revenue estimates and forecasts, 2018 - 2030 (USD Million
  • Fig. 20 Injectable mode of administration market revenue estimates and forecasts, 2018 - 2030 (USD Million
  • Fig. 21 Other modes of administration market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 North America erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Spain erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Norway erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Denmark erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Sweden erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 China erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 South Korea erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Middle East and Africa erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)